New Search

If you are not happy with the results below please do another search

2034 search results for:

72

TherageniX awarded £995K grant to develop powdered gene therapy for bone regeneration

TherageniX, a University of Nottingham spin out pioneering a dry powder gene therapy formulation for bone graft augmentation, and its collaborator, the University of Nottingham, have been awarded a £995,000 grant from Innovate UK, the UK’s innovation agency. The funding will support the development of the company’s gene therapy in a powder, a non-viral gene delivery […]

74

Agilent Technologies sells Resolution Bioscience to Exact Sciences

Agilent Technologies will sell Resolution Bioscience to Exact Sciences, a leading provider of cancer screening and diagnostic tests. Financial terms of the agreement were not disclosed. Resolution Bioscience develops and commercializes next-generation sequencing-based precision oncology solutions. Agilent acquired the company in 2021.

75

SMi Systems secures UK patent for breakthrough single-molecule imaging technology

SMi Systems has secured a patent from the UK Intellectual Property Office (IPO) for the single-molecule imaging technologies that underpin its super-resolution multi-omic platform. The patented technology consists of highly specialised optics that allow SMi to view single molecules at unprecedented resolution. When combined with the company’s uniquely designed consumables and deep learning techniques, the […]

78

Imaging breakthrough: speckle diffraction tomography reveals nanoscale features in thick biological specimens

For years, capturing detailed three-dimensional images of complex biological specimens has posed a major challenge due to their intricate composition and the multiple scattering of light. A game-changing moment has arrived, as scientists from the MIT Laser Biomedical Research Center and the Chinese University of Hong Kong have introduced an innovative method called speckle diffraction […]

80

EMA recommends authorisation of first RSV vaccine for infants

The European Medicines Agency (EMA) has recommended granting a marketing authorisation in the European Union (EU) for Pfizer Europe’s Abrysvo ( EMA opinion on Abrysvo: https://bit.ly/45jVL7Z ), a vaccine to protect against disease caused by the respiratory syncytial virus (RSV). Abrysvo is the first RSV vaccine indicated for passive immunisation of infants from birth through […]